Neoplasie della mammella
Anno: 1998
-
Riferimento:Lancet. 1998 Oct 24;352(9137):1388-9.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Nat Immun. 1998;16(1):27-33.Azione della melatonina:Natural cancer therapy with MLT (20 mg/day orally in the dark period) plus A. vera extracts may produce some therapeutic benefits.Target:MLT plus Aloe vera.
Anno: 1999
-
Riferimento:J Pineal Res. 1999 Apr;26(3):169-73Azione della melatonina:Melatonin (orally at 20 mg/day) may contribute to the realization of chemotherapy in metastatic cancer patients.Target:Thrombocytopenia.
-
Riferimento:Environ Health Perspect. 1999 Feb;107 Suppl 1:145-54. Review.Azione della melatonina:Melatonin-breast cancer and EMF-breast cancer hypotheses.Target:Electromagnetic fields (EMF).
-
Riferimento:FASEB J. 1999 May;13(8):857-68.Azione della melatonina:Melatonin interferes with the activation of estrogen receptor by estradiol.Target:Estrogen receptor DNA.
-
Riferimento:Adv Exp Med Biol. 1999;460:345-62. Review.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:J Pineal Res. 1999 Jan;26(1):1-8.Azione della melatonina:Melatonin may have a role in the regulation of peripheral blood cell counts.Target:Serum melatonin/circadian rhythms.
-
Riferimento:J Pineal Res. 1999 Mar;26(2):65-100. Review.Azione della melatonina:Decreased melatonin production leads to increased risk of breast cancer.Target:Light at night/electromagnetic fields (EMF).
-
Riferimento:Natl Toxicol Program Tech Rep Ser. 1999 Aug;489:1-148.Azione della melatonina:No evidence that magnetic fields promoted the development of mammary gland neoplasms initiated by the administration of dimethylbenzanthracene.Target:DMBA/ELF 50 Hz
-
Riferimento:Biol Signals Recept. 1999 Jan-Apr;8(1-2):75-8.Azione della melatonina:Melatonin may influence the proliferation of tumor cells via RZR/ROR receptors.Target:CGP 52608 ligand for RZR/ROR receptors.